Trial Profile
An open-label study to evaluate the long-term safety and tolerability of AFQ056 in adolescent patients with Fragile X Syndrome
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 13 Feb 2019
Price :
$35
*
At a glance
- Drugs Mavoglurant (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Feb 2019 This trial has been Discontinued in United Kingdom, according to European Clinical Trials Database.
- 07 Dec 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 21 May 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Dec 2015 to 1 Aug 2014.